ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,187.46
0.28%
Dow Jones
41,198.08
0.59%
Gold vs US Dollar
2,467.65
0.25%
Brent Oil
84.715
0.27%
Bitcoin
64,566.70
0.75%
Pepperstone
Advertisement
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Get Started
Unknown symbol
Date:
Sort by:
DateTimeSourceHeadlineSymbolCompany
18/07/202406:30UK RegulatoryDNA Plc’s Half-Year Financial Report 2024: Total revenues, EBITDA, and operating result continued to improve
18/07/202406:30UK RegulatoryNicox : Résumé financier du deuxième trimestre 2024LSE:0RCQNicox Sa
18/07/202406:30UK RegulatoryBGHL (EUR): NAV(s)LSE:BGHLBoussard & Gavaudan Holding Limited
18/07/202406:30UK RegulatoryViridien Announces its Q2 Financial Results on Tuesday 30th July 2024, after Market CloseEU:VIRIViridien
18/07/202406:25UK RegulatoryNew plan period in the long-term incentive scheme directed to Aspocomp’s managementLSE:0DG8Aspocomp Group Oyj
18/07/202406:21PR Newswire (US)GameFi + DePIN: Japanese Web3 Organization Rona Redefines Next-Generation Consoles
18/07/202406:19PR Newswire (US)MicuRx Presents Innovative Antibiotic Research Results at the 7th World Bronchiectasis Conference
18/07/202406:05UK RegulatoryTGS Quarterly DividendTG:TGCTGS ASA
18/07/202406:02UK RegulatoryTelenor continues to deliver on security offering and growthTG:TEQTelenor ASA
18/07/202406:00UK RegulatoryCoop Pank unaudited financial results for Q2 2024
18/07/202406:00UK RegulatoryBioSenic releases new in-depth analysis of its positive phase 2 clinical data for optimal administration scheme for its next late-stage trial of arsenic trioxide (ATO) targeting cGvHDEU:BIOSBiosenic
18/07/202406:00UK RegulatoryStart of Day Message
18/07/202406:00UK RegulatoryTelia Lietuva results for 6 months of 2024LSE:0G8JTelia Lietuva Ab
18/07/202406:00UK RegulatoryVivoryon Therapeutics N.V. Announces New Data Showing Unique Treatment Effects of Varoglutamstat on Kidney Function in Patients with Diabetes and Outlines Proposed Clinical Development Plan in Diabetic Kidney DiseaseTG:05YVivoryon Therapeut
18/07/202406:00UK RegulatoryHexagon Purus ASA: Results for the second quarter 2024TG:0QJHexagon Purus ASA
18/07/202406:00UK RegulatoryVivoryon Therapeutics N.V. Announces New Data Showing Unique Treatment Effects of Varoglutamstat on Kidney Function in Patients with Diabetes and Outlines Proposed Clinical Development Plan in Diabetic Kidney DiseaseEU:VVYVivoryon Therapeut
18/07/202406:00UK RegulatoryTGS Announces Q2 2024 ResultsTG:TGCTGS ASA
18/07/202406:00UK RegulatoryBioSenic réalise une nouvelle analyse approfondie de ses données cliniques positives de phase 2 en vue d'un schéma d'administration optimal pour son prochain essai clinique de phase avancée sur le trioxyde d'arsenic (ATO) ciblant la cGvHDEU:BIOSBiosenic
18/07/202406:00UK RegulatoryHexagon Purus ASA: Results for the second quarter 2024LSE:0AC1Hexagon Purus Asa
18/07/202406:00UK RegulatoryBioSenic réalise une nouvelle analyse approfondie de ses données cliniques positives de phase 2 en vue d'un schéma d'administration optimal pour son prochain essai clinique de phase avancée sur le trioxyde d'arsenic (ATO) ciblant la cGvHDLSE:0R55Biosenic Sa
18/07/202406:00UK RegulatoryVivoryon Therapeutics N.V. Announces New Data Showing Unique Treatment Effects of Varoglutamstat on Kidney Function in Patients with Diabetes and Outlines Proposed Clinical Development Plan in Diabetic Kidney DiseaseLSE:0R3MVivoryon Therapeutics Nv
18/07/202406:00UK RegulatoryBioSenic releases new in-depth analysis of its positive phase 2 clinical data for optimal administration scheme for its next late-stage trial of arsenic trioxide (ATO) targeting cGvHDLSE:0R55Biosenic Sa
18/07/202406:00UK RegulatoryNokia Corporation Report for Q2 and Half Year 2024BIT:1NOKIANokia Corp
18/07/202406:00UK RegulatoryNokia Corporation Report for Q2 and Half Year 2024BIT:NOKIANokia Corp
18/07/202406:00UK RegulatoryBAWAG Group publishes Q2 2024 results: Net profit € 175 million and RoTCE 24.3%TG:0B2Bawag Group AG
18/07/202406:00UK RegulatoryBAWAG Group: Q2 2024 Nettogewinn von 175 Mio. € und RoTCE von 24,3%TG:0B2Bawag Group AG
18/07/202406:00UK RegulatoryNokia Corporation Report for Q2 and Half Year 2024TG:NOA3Nokia Corp
18/07/202406:00UK RegulatoryPR Newswire - Start of Day
18/07/202406:00PR Newswire (US)Renalys Pharma announces first patient dosed in registrational Phase III clinical trial of sparsentan for IgA nephropathy in Japan
18/07/202405:55UK RegulatoryTGS Announces Extension to its Ocean Bottom Node Acquisition Campaign in West AfricaTG:TGCTGS ASA

Your Recent History

LSE
EDEN
Eden Research
LSE
GDR
Genedrive
LSE
PANR
Pantheon Resources
LSE
PPP
Pennpetro Energy
LSE
MIN
Minoan
LSE
ALBA
Alba Mineral Resources
LSE
VAST
Vast Resources
LSE
JLP
Jubilee Metals
LSE
SRSP
Sirius Petroleum
LSE
EZJ
Easyjet
LSE
SRC
Sigmaroc
LSE
ENET
Ethernity Networks
LSE
QBT
Quantum Blockchain Techn...
LSE
BGO
Bango
LSE
POS
Plexus
LSE
FLTR
Flutter Entertainment
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved